Varicella zoster virus the ACIP recommended a second dose of vaccine before school entry to ensure the maintenance of high levels of varicella immunity. In 2006, the United States Food and Drug Administration approved Zostavax for the prevention of shingles. Zostavax is a more concentrated formulation of the Varivax vaccine, designed to elicit an immune response in older adults whose immunity to VZV wanes with advancing age. A systematic review by the Cochrane Library shows that Zostavax reduces the incidence of shingles by almost 50%. Shingrix is a "V. zoster" vaccine developed by GlaxoSmithKline which was approved in the United States by the
Psychogenic disease to be psychogenic include psychogenic seizures, psychogenic polydipsia, psychogenic tremor, and psychogenic pain. There are problems with the assumption that all medically unexplained illness must have a psychological cause. It always remains possible that genetic, biochemical, electrophysiological, or other abnormalities may be present which we do not have the technology or background to identify. The term "psychogenic disease" is often used in a similar way to "psychosomatic disease". However, the term "psychogenic" usually implies that psychological factors played a key causal role in the development of the illness. The term "psychosomatic" is often used in a broader way to describe